Drug Of Abuse Testing Services Market Industry Report 2034: Size, Share, Trends and Opportunities

Over the past few years, there has been an increase in the consumption of illicit drugs, alcohol, and other recreational chemicals particularly among the younger generation in the developed countries.

Product innovations, technological advancements, and the introduction of regulatory policies have been detailed in the report to enable businesses to make more informed decisions. Furthermore, the impact of the COVID-19 pandemic on the drug of abuse testing services market demand has been examined in the study. The report is a must-read for anyone looking to develop effective strategies and stay ahead of the curve.

Know more about this report: Download Sample Report

There is a rise in government monitoring to contain drug abuse also significantly driving the testing services market growth. According to the statistics published by the U.S.-based dedicated organization, United Nations Office on Drugs and Crime (UNODC), in 2019, approximately 35 million people across the globe are suffering from drug abuse disorders and are seeking testing and treatment services.

It is also being estimated that there are over 188 million users of cannabis all over the world. Moreover, National Center for Drug Abuse Statistics (NCDAS), estimated that there are around 1.5 to 5 percent of the diseases diagnosed through testing are due to illegal consumption of drugs and other recreational chemicals.

Moreover, based on the Federal Drug-Free Workplace program norms, a condition under which all federal employees must avoid consumption of any kind during office hours. It facilitates the certification of agencies free from the illicit use of drugs and initiates potential sources for potential toxicology testing services centers. SAMHSA center of drug abuse testing services also supervises certified labs to work under the mandated guidelines.

Adoption of such programs to test drug abuse in few sensitive institutions like law enforcement, public health and safety, and national security is expected to drive the testing services market. All testing services provided by both public and private entities should be in accordance with legal considerations. Such authorities have all power and legal mandate to decide the condition and situation under which testing services should be provided.

Know more about this report: Download Sample Report

Report Segmentation

The market is primarily segmented on the basis of drug type, end-use, and region.

Source: Polaris Market Research Analysis

Know more about this report: Download Sample Report

Insight by Drug Type

The cannabis abuse testing services market segment accounted for the largest revenue share in 2020. This high share is attributed to its highest consumption all over the world. As per the market statistics published by the Substance Abuse and Mental Health Services Administration, in 2018, a particular drug was commonly used in the U.S., and it is being estimated that over 43.5 million people are regular users.

However, the opioids abuse testing services market segment witness to register highest growth over the market study period. Such growth is due to the ongoing opioid crisis in western countries. According to the data stated by the National Center for Drug Abuse Statistics, in 2018, more than 2 million individuals in the U.S. are a victim of the opioid crisis.

The most prominent among these include heroin and prescription-based pain relievers. Moreover, key players in the market for drug of abuse testing services are introducing organic strategies to expand their capabilities for opioid abuse testing market.

Geographic Overview

In 2020, North America drug of abuse testing services market accounted for the largest revenue share and is expected to maintain its dominance over the assessment period. Key factors responsible for the testing services market growth include the rising prevalence of substance abuse and the opioid crisis in the region.

Moreover, stronger government measures and the ongoing situation of COVID-19 in the region also favored the increase in consumption of illicit drugs. However, country-wise lockdowns reduced the market demand for workplace drug testing services, owing to the dormant market growth scenario.

However, Asia Pacific drug of abuse testing services is projected to witness the highest market growth over the assessment period. The increasing prevalence of drug abuse among Asian countries coupled with improving testing capabilities is primarily responsible for such market growth. However, lack of transparent policies towards workplace testing, and country-wise lockdowns may hamper the region’s drug of abuse testing services market growth.

List Of Key Companies

• Quest Diagnostics Incorporated
• Laboratory Corporation of America (Labcorp)
• Psychemedics Corporation
• DISA Global Solutions
• Abbott Laboratories
• Omega Laboratories
• Clinical Reference Laboratory
• Cordant Health Solutions
• Synergy Health / Steris
• Alere Toxicology

Recent Industry Developments

In November 2026, Labcorp completed its acquisition of Millennium Health, a specialist laboratory that provides drug testing and monitoring services. The acquisition expands Labcorp’s toxicology portfolio and offers wider access to testing for patients being treated for chronic pain, substance use disorders, and other conditions that require drug monitoring. This change has a direct effect on the market for drug-of-abuse testing services because it makes it easier for labs to find both legal and illegal drugs and connects specialized services to a bigger diagnostic network. (Source: Labcorp)

In July 2026, Quest Diagnostics reported in its Drug Testing Index that 19.1% of US workforce hair drug tests were positive in 2025, up from 13.1% in 2021, while urine positivity was 4.3%. Marijuana accounted for over half of hair positives, while fentanyl positivity nearly halved. (Source: Quest Diagnostics)

In April 2026, the US acting attorney general signed an order moving medical marijuana from Schedule I to Schedule III, a change that could affect drug testing rules in federal programmes over time. (Source: Clinical Lab Products)

In December 2025, Quest Diagnostics added more oral fluid drug-monitoring tests, including a nine-panel screening menu and tests for drugs such as fentanyl, cocaine, methamphetamine, benzodiazepines and opioids. The expanded portfolio supports laboratory based drug screening of oral fluid specimens and a replacement for routine urine based testing in appropriate clinical settings. The development is part of continued innovation in analytical testing menus and non-invasive specimen collection. (Source: Quest Diagnostics)